X4 PHARMACEUTICALS INC. - COMMON STOCK

X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome

05 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program

10 Aug 2023 06:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

08 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital

03 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023

02 Aug 2023 08:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Jun 2023 16:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Expected to Join Russell 3000® Index

13 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Jun 2023 16:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

16 May 2023 16:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market

16 May 2023 08:30:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update

04 May 2023 06:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023

26 Apr 2023 08:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

21 Mar 2023 06:05:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023

07 Mar 2023 08:01:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Mar 2023 16:05:01 By Nasdaq GlobeNewswire

X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia

12 Dec 2022 08:30:00 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Prices $65.0 Million Public Offering

07 Dec 2022 08:43:05 By Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Proposed Public Offering

06 Dec 2022 18:26:02 By Nasdaq GlobeNewswire